BI0112 ADC

BI0112 ADC is an antibody-drug conjugate (ADC) currently in the discovery phase of development by Protheragen. It is designed to target fibroblast growth factor receptor 2b (FGFR2b), a cell surface protein that is frequently overexpressed in various solid tumors, including gastric and breast cancers. The therapeutic strategy involves the specific binding of the antibody component to FGFR2b, leading to the internalization of the ADC and the subsequent release of a cytotoxic payload within the tumor cells. This targeted approach aims to maximize anti-tumor efficacy while minimizing off-target systemic toxicity. The program is part of Protheragen's oncology pipeline focusing on precision medicine for solid malignancies.